FDA Employees, Pharma and Bio Employees, Medical Advocacy Groups, Patients with Serious Illnesses, Other with interest in the Medical Community

Please comment and share your thoughts on the issue of the US FDA taking the Metastatic Breast Cancer Drug Avastin off label.

Is it the right decision or could it be handled differently?

How will this affect drug development in the U.S.?

Do you fear that this will slow development of other drugs for other serious illnesses?

What does this mean for our economic competitiveness in pharma and bio?

Is the FDA too harsh in its dealings with drug companies or does it need to crack down further on dangerous drugs reaching market?